Curious minds select the most fascinating podcasts from around the world. Discover hand-piqd audio recommendations on your favorite topics.
I have worked in both University and Private sector labs and studied biology at UT Austin.
After leaving academic research I helped form Prophase BioStudios and built a laboratory out of a local Hackerspace.
Using the laboratory at Prophase BioStudios I started doing my own independent experiments that led me to create my Biomanufacturing company, Portunus.
My interests are primarily in biotechnology, particularly in the realms of fabrication and human enhancement.
The Bio Report is interviewing Elizabeth Jeffords chief strategist and commercial officer of the company Alkahest about their use of blood serum extracted proteins. There is current research going into the understanding of Eotaxin as a tool for anti-aging. Despite being more common in older patients it is suspected that Eotaxin has anti-aging properties.
Through its' partner Grifols, Alkahest produces plasma fractions; containing a particular molecule called 4290. These plasma fractions are neurogenerative and anti-inflammatory when tested on lab mice. This neurogenesis would imply a potential to reverse the decline and inflammation associated with Alzheimer's. Jeffords plans to test the serum on Alzheimer's patients in the summer of 2019.
Griofols manufactures these plasma fractions from blood donors, known as pulled plasma, the homogenized mixture of plasma form many different donors. The production process is made safer through this mixture of serum by accounting for abnormalities in the plasma of a particular donor.
Additional molecules that are being studied for anti-aging effects are GRF6019 and GRF6021. As well as investigating these other molecules, Alkahest is in the midst of testing their technology on Age Related Macular Degeneration and Parkinson's as well as Alzheimers.